These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22983576)

  • 1. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
    Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N
    Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
    Prebet T; Fenaux P; Vey N;
    Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503
    [No Abstract]   [Full Text] [Related]  

  • 3. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
    Kamiya T; Nakazato T
    Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221
    [No Abstract]   [Full Text] [Related]  

  • 4. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
    Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
    Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematology: Azacitidine improves survival in myelodysplastic syndromes.
    Rose MG
    Nat Rev Clin Oncol; 2009 Sep; 6(9):502-3. PubMed ID: 19707240
    [No Abstract]   [Full Text] [Related]  

  • 6. Myelodysplasia, megakaryocytes, and methylation.
    Steensma DP
    Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
    [No Abstract]   [Full Text] [Related]  

  • 7. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
    Santini V; Prebet T; Fenaux P; Gattermann N; Nilsson L; Pfeilstöcker M; Vyas P; List AF
    Leuk Res; 2014 Dec; 38(12):1381-91. PubMed ID: 25444075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
    Kantarjian HM
    J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
    [No Abstract]   [Full Text] [Related]  

  • 9. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
    Duong VH; Lin K; Reljic T; Kumar A; Al Ali NH; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):711-5. PubMed ID: 24054159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
    Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
    Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
    Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
    Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
    [No Abstract]   [Full Text] [Related]  

  • 13. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
    Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
    Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
    Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
    Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829
    [No Abstract]   [Full Text] [Related]  

  • 15. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
    Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B
    Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
    Carella AM
    Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976
    [No Abstract]   [Full Text] [Related]  

  • 17. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes.
    Seymour JF; Bennett JM; List AF; Mufti GJ; Gore SD; Fenaux P; Santini V; Hetzer J; Songer S; Skikne BS; Beach CL
    Br J Haematol; 2014 Apr; 165(1):49-56. PubMed ID: 24467613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Peterlin P; Cluzeau T; Jullien M; Ngo Nloga AM; Calleja A; Angeli E; Chevallier P; Guillaume T; Garnier A; Le Bourgeois A; Le Gouill S; Fenaux P; Adès L; Bally C
    Br J Haematol; 2020 Aug; 190(3):461-464. PubMed ID: 32394477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.